The United Kingdom and the United States have established a major bilateral deal that will guarantee no import taxes on British pharmaceutical shipments going into the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the NHS. This move secures that duties on these vital exports will stay at zero for a timeframe of three years.
This development comes after earlier statements to significantly raise duties on branded drug products, with increases floated as high as double the cost.
"This agreement between the United Kingdom bolsters the worldwide climate for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," an announcement declared.
Trade Significance
Drugs are one of the UK's biggest exports to the United States, which is by far the biggest destination for leading UK drugmakers.
Statistics reveal that in the year prior to last September, the UK shipped drugs worth £11.1bn to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal secures jobs, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," a government official remarked.
Detailed UK Commitments
The pact entails several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to control costs will be limited at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
This agreement follows a long-running tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
These tensions were intensified by assertions that American customers were charged several times more for the same drugs than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
